Downregulation of ACC expression suppresses cell viability and migration in the malignant progression of breast cancer

Exploring new diagnostic biomarkers and molecular targets is of great importance in breast cancer treatment. The present study investigated the effects of acetyl-CoA carboxylase (ACC) expression interference on the malignant progression of breast cancer cells. ACC expression was knocked down using a lentiviral vector and this was verified by quantitative polymerase chain reaction and western blotting. MCF-7 and MDA-MB-231 breast cancer cells were randomly allocated into the following groups: Normal breast cancer cells (control), breast cancer cells transduced with a negative control lentiviral vector and breast cancer cells transduced with an ACC knockdown lentiviral vector. Screening for stable transgenic strains was successful. Cell viability, apoptosis and migration were determined using Cell Counting Kit-8, flow cytometry and scratch test, respectively. The protein expression levels of N-cadherin, Vimentin and Bax were detected by western blotting. In addition, a nude mouse model of subcutaneous metastatic tumor was established using MCF-7 breast cancer cells, and tumor volume was assessed. Furthermore, pathological condition and apoptosis were detected using hematoxylin and eosin, and TUNEL staining, respectively. The protein expression levels of N-cadherin, Vimentin and Bax were detected by western blotting. The in vitro experiments showed that knockdown of ACC expression significantly decreased the viability and migration, and increased the apoptosis of MCF-7 and MDA-MB-231 breast cancer cells. In vivo experiments revealed that ACC knockdown effectively reduced the tumor volume in nude mice, and promoted tumor cell apoptosis. Both in vitro and in vivo experiments showed that ACC knockdown can reduce the protein expression levels of N-cadherin and Vimentin, and increase Bax expression. These findings suggested that downregulation of ACC expression may significantly reduce the malignant progression of breast cancer, and could be considered a potential therapeutic target.

[1]  Bhargab Kalita,et al.  Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[2]  J. Dai,et al.  Coding variants in the PCNT and CEP295 genes contribute to breast cancer risk in Chinese women. , 2021, Pathology, research and practice.

[3]  J. Palacios,et al.  Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma , 2021, International journal of molecular sciences.

[4]  Jiabao Zhang,et al.  Anticancer effects of Traditional Chinese Medicine on epithelial-mesenchymal transition(EMT) in breast cancer: Cellular and molecular targets. , 2021, European journal of pharmacology.

[5]  D. Tong Unravelling the Molecular Mechanisms of Prostate Cancer Evolution from Genotype to Phenotype. , 2021, Critical reviews in oncology/hematology.

[6]  T. Rachner,et al.  The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone , 2021, International journal of molecular sciences.

[7]  K. Sanber,et al.  Targeting hydrogen sulphide signaling in breast cancer , 2020, Journal of advanced research.

[8]  L. Qiao,et al.  Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C/EBPα/SREBP-1 pathway. , 2020, Acta biochimica et biophysica Sinica.

[9]  Yong Qin,et al.  Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors , 2019, Expert opinion on investigational drugs.

[10]  Cunshuan Xu,et al.  ACC1 is overexpressed in liver cancers and contributes to the proliferation of human hepatoma Hep G2 cells and the rat liver cell line BRL 3A , 2019, Molecular medicine reports.

[11]  M. Díaz-Zaragoza,et al.  Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). , 2014, Oncology reports.

[12]  Danyang Yu,et al.  Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis , 2014, Medical Oncology.

[13]  Sebastian Munck,et al.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. , 2010, Cancer research.

[14]  F. van der Leij,et al.  Regulatory enzymes of mitochondrial β‐oxidation as targets for treatment of the metabolic syndrome , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[15]  J. Corbett Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007 – 2008 , 2009, Expert opinion on therapeutic patents.

[16]  Margaret S. Wu,et al.  Control of Cell Growth and Survival by Enzymes of the Fatty Acid Synthesis Pathway in HCT-116 Colon Cancer Cells , 2008, Clinical Cancer Research.

[17]  G. Shulman,et al.  Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. , 2006, The Journal of clinical investigation.

[18]  D. Moller,et al.  Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome , 2006, Endocrine.

[19]  H. J. Harwood,et al.  Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. , 2005, Expert opinion on therapeutic targets.

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  Somesh D. Sharma,et al.  Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. , 2006, Molecular and cellular biochemistry.

[22]  M. Dowsett Preoperative models to evaluate endocrine strategies for breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Parlee,et al.  This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .